Transition to Targeted Therapies Improved the Prognosis and Increased the Utilization of Medical Treatments among Patients with Synchronous Metastatic Renal Cell Cancer

<div>Kaplan–Meier analysis of overall survival in patients who did not receive drug therapies for histologically confirmed renal cell cancer. For this analysis, the follow-up time was limited to 60 months due to low number of patients surviving longer.</div>

International Journal of Surgical Oncology

fig1

Figure 1

Figure 1: Transition to Targeted Therapies Improved the Prognosis and Increased the Utilization of Medical Treatments among Patients with Synchronous Metastatic Renal Cell Cancer 

Figure 1 | Transition to Targeted Therapies Improved the Prognosis and Increased the Utilization of Medical Treatments among Patients with Synchronous Metastatic Renal Cell Cancer 